NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

BMY really don't seem to have a clue...

They're running a new randomized open-label P2 in recurrent GBM.

Two arms.

Arm 1. Nivo plus standard dose Bev.

Arm 2. Nivo plus reduced dose Bev

Primary outcome: OS12.

Secondary outcome: OS. Measured up to 3yrs.

https://clinicaltrials.gov/ct2/show/study/NCT03452579#contacts



What do they hope to learn?

I expect the only things they will learn are that Bev caps survival from recurrence at 10 months max with considerable toxicity, and Nivo reduces PFS compared to giving nothing, but adds toxicity.

As was previously demonstrated in Checkmate 143, a P3 no less, when Nivo reduced PFS to 1.5 months...

https://academic.oup.com/neuro-oncology/article/19/suppl_3/iii21/3743874



Pity the patients.